Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer

• US 10,429,390 B2
• Filed: 12/18/2013
• Issued: 10/01/2019
• Est. Priority Date: 12/18/2012
• Status: Active Grant

• Current Assignee: Biocare Medical LLC
• Original Assignee: Biocare Medical LLC
• Inventors: Tacha, David
• Primary Examiner(s): Aeder, Sean E
• Application Number:
  US14/652,407
• Publication Number:
  US 20150309035A1
• Time in Patent Office: 2,113 Days
• Field of Search: 5303871
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57423 of lung

Abstract

The present invention relates to compositions and detection systems of antibodies or fragments thereof, wherein at least two antibodies or fragments thereof binds specifically to squamous cell carcinoma (SCC) and/or adenocarcinoma (ADC). Methods for using the antibodies in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits including such compositions and detection systems.

Claims

1. A lung cancer detection system comprising:

a cocktail of two primary antibodies,

wherein a first primary antibody of said cocktail comprises an anti-p40 mouse monoclonal antibody, clone BC28, which specifically binds to squamous cell carcinoma (SCC); and

wherein a second primary antibody of said cocktail comprises an anti-TTF-1 mouse monoclonal antibody which specifically binds to adenocarcinoma (ADC).

2. A lung cancer detection system according to claim 1 and further comprising at least one antibody-enzyme conjugate.

3. A lung cancer detection system according to claim 2 and further comprising at least one chromogen.

4. A lung cancer detection system according to claim 2 wherein said at least one antibody-enzyme conjugate comprises an antibody selected from a group consisting of anti-rabbit antibody, anti-mouse antibody, anti-chicken antibody, anti-horse antibody, anti-rat antibody, anti-goat antibody, anti-sheep antibody, and any combination thereof.

5. A lung cancer detection system according to claim 4 wherein said at least one antibody-enzyme conjugate comprises an enzyme selected from a group consisting of horseradish peroxidase (HRP), alkaline phosphate (AP), glucose oxidase, β

-galactosidase, and any combination thereof.

6. A lung cancer detection system according to claim 3 wherein said at least one chromogen is selected from a group consisting of 3,3′

-diaminobenzidine (DAB);

Fast Red;

3-amino-9-ethylcarbazole (AEC);

Fast Blue;

3,3′

,5,5′

-tetramethylbenzidine (TMB);

5-Bromo-4-chloro-3-indolyl phosphate (BCIP);

nitro blue tetrazolium (NBT);

tetranitrobluetetrazolium (TNBT);

New fuschin, 5-bromo-4-chloro-3-indolyl-β

-D-galactopyranoside (X-Gal);

5-Bromo-3-indolyl β

-D-galactopyranoside (Bluo-Gal); and

any combination thereof.

7. A lung cancer detection system according to claim 2 wherein an antibody of said at least one antibody-enzyme conjugate binds to at least one of said two primary antibodies.